X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, F-star will grant Takeda a worldwide, exclusive royalty-bearing licence to research, develop, and commercialize a bispecific antibody directed towards an undisclosed immuno-oncology target using F-star’s proprietary Fcab™ and mAb2 ™ platforms.
Lead Product(s): Bispecific Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 22, 2023
Details:
FS118 is a dual checkpoint inhibitor targeting PD-L1 and LAG-3. FS118 is designed to provide unique pharmacology, that drives PD-L1 dependent LAG-3 shedding and receptor down-regulation, via bispecific activity, and potentially offering a more durable response in patients.
Lead Product(s): FS118
Therapeutic Area: Oncology Product Name: FS118
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: invoX Pharma Limited
Deal Size: $161.0 million Upfront Cash: $161.0 million
Deal Type: Acquisition March 08, 2023
Details:
FS222 targets critical tumoral immune-suppressing pathways via PD-L1 checkpoint blockade and exhibited important costimulatory effect of potent clustering and activation of CD137, which in turn, promotes T cell activation and enhanced cytotoxic T cell responses.
Lead Product(s): FS222
Therapeutic Area: Oncology Product Name: FS222
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Details:
FS118 is a first-in-class tetravalent bispecific antibody binding to LAG-3 and PD-L1, resulting in the reversal of immune suppression. FS118 was well tolerated with no treatment-related serious adverse events and no dose-limiting toxicity, up to 20mg/kg.
Lead Product(s): FS118
Therapeutic Area: Oncology Product Name: FS118
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
Under the terms of the agreement, F-star will grant Takeda a worldwide, exclusive royalty-bearing license to research, develop, and commercialize a bispecific antibody against an immuno-oncology target using F-star’s proprietary Fcab™ and mAb2 ™ platforms.
Lead Product(s): Bispecific Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $41.0 million Upfront Cash: $1.0 million
Deal Type: Licensing Agreement July 20, 2022
Details:
F-star’s unique next-generation tetravalent (2+2) bispecific antibody platform complements Sino Biopharm’s existing capabilities and reinforces its global oncology pipeline including FS118.
Lead Product(s): FS118
Therapeutic Area: Oncology Product Name: FS118
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: invoX
Deal Size: $161.0 million Upfront Cash: $161.0 million
Deal Type: Acquisition June 23, 2022
Details:
FS222, a CD137/PD-L1 mAb2 bispecific antibody targets PD-L1, the immune checkpoint protein that regulates the balance of activated T cells in the immune system and is overexpressed on many solid tumors.
Lead Product(s): FS222
Therapeutic Area: Oncology Product Name: FS222
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2021
Details:
Under the terms of the agreement, F-star will grant Janssen, a exclusive royalty-bearing license to research, develop, and commercialize up to five novel bispecific antibodies directed to Janssen therapeutic targets using F-star’s proprietary Fcab™ and mAb2™ platforms.
Lead Product(s): Tetravalent Bispecific Antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: $1,367.5 million Upfront Cash: $17.5 million
Deal Type: Licensing Agreement October 20, 2021
Details:
FS120, a first-in-class OX40 and CD137 tetravalent dual T cell agonist used in patients with advanced malignancies. Safety and PK/PD data trigger initiation of the previously announced FS120 and KEYTRUDA® (pembrolizumab) combination study, scheduled to start in Q3 2022.
Lead Product(s): FS120
Therapeutic Area: Oncology Product Name: FS120
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2021
Details:
Under the agreement, MSD will supply KEYTRUDA for a combination arm that will be included in the adaptive Phase 1 clinical protocol of FS120, F-star’s first-in-class dual-agonist tetravalent bispecific antibody targeting CD137 and OX40 in patients with advanced cancer.
Lead Product(s): FS120,Pembrolizumab
Therapeutic Area: Oncology Product Name: FS120
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 04, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
